Factors associated with immediate transfusion reactions in a university blood center: an analytical, retrospective study
DOI:
https://doi.org/10.11606/issn.2176-7262.v53i3p275--282Keywords:
Risk Factors, Transfusion Reaction, Blood TransfusionAbstract
An analytical, cross-sectional, retrospective study. Objectives: Investigating the relationship among immediate transfusion reactions, demographic and clinical characteristics of patients, and transfusion-related characteristics in a university blood center. Methodology: The study was performed with data regarding blood transfusions of the blood center at Universidade Federal de São Paulo in 2016. Patient’s demographic and clinical characteristics and the characteristics of the immediate transfusion reactions were collected. Possible associations were evaluated using Fishers, Mann-Whitney, Chi-square, and Student’s t-test. Statistically significant associations with p≤0.05 were considered. Results: Data from 320 patient records were analyzed, totaling 938 blood transfusions. Of the blood products transfused, 90.3% were red blood cells concentrate administered by nursing assistants in 43.8% of the situations. Immediate transfusion reactions occurred in 4.3% of the situations (n=40). The most common transfusion reaction was fever (47.5%), followed by pruritus (22.5%). The transfusion reactions were more frequent in older patients (p=0.0037) who received two blood transfusions compared to one (p<0.0001), consequently more transfusion bags (p=0.0002), greater total transfused volume (p <0.0001), and longer length of administration (p=0.0017). Patients with aplastic anemia, acute myeloid leukemia, and solid organ neoplasms had immediate transfusion reactions more frequently than patients with other diagnoses (p <0.05). Conclusion: The occurrence of immediate transfusion reactions was related to age, medical diagnosis, number of blood transfusions, number of transfused bags, total transfused volume, and transfusion time. Knowledge of these factors may support specific training for immediate transfusion reactions surveillance.
Downloads
References
Turner ML. Safety of blood, blood derivatives, and plasma-derived products. Handb Clin Neurol. 2018;153:463-72.
Jones JM, Sapiano MRP, Savinkina AA, Haass KA, Baker ML, Henry RA, et al. Slowing decline in blood collection and transfusion in the United States – 2017. Transfusion. 2020; 60(S2):S1-S9. doi: 10.1111/trf.15604
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada e Temática. Caderno de informação: sangue e hemoderivados: dados de 2016. [citado 2020 Jun 07]. Brasília (DF): Ministério da Saúde; 2018 Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/caderno_informacao_sangue_hemoderivados_2016.pdf.
Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA. 2016;316(19):2025-35.
Frazier SK, Higgins J, Bugajski A, Jones AR, Brown MR. Adverse Reactions to Transfusion of Blood Products and Best Practices for Prevention. Crit Care Nurs Clin North Am. 2017;29(3):271-90.
Politis C, Wiersum JC, Richardson C, Robillard P, Jorgensen J, Renaudier P, et al. The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results. Vox Sang. 2016;111(4): 409-17.
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Especializada e Temática. Guia para uso de Hemocomponentes [Internet]. Brasília (DF); 2015 [citado 2019 Out 20]. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/guia_uso_hemocomponentes_2ed.pdf.
Brasil. Agência Nacional de Vigilância Sanitária. Relatório de Hemovigilância 2015. [citado 2020 Jun 07]. Brasília (DF): Anvisa, 2016. Disponível em: http://portal.anvisa.gov.br/documents/33868/405589/Hemovigil%C3%A2ncia+no+Brasil+-+Relat%C3%B3rio+consolidado+2007+-+2015/51add6c1-0a15-4c18-9089-36a31e4cdd39.
Brasil. Ministério da Saúde. Gabinete do Ministro. Portaria nº1660, de 22 de julho de 2009. Institui o Sistema de Notificação e Investigação em Vigilância Sanitária-VIGIPOS, no âmbito do Sistema Nacional de Vigilância Sanitária, como parte integrante do Sistema Único de Saúde-SUS. Diário oficial da União, Brasília, 22 jul. 2009. [citado 2020 Junho 05]. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2009/prt1660_22_07_2009.html
Grandi JL, Grell MC, Areco KC, Barbosa DA. Hemovigilância: a experiência da notificação de reações transfusionais em Hospital Universitário. Rev Esc Enferm USP. 2018;52:e03331.
Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA. 2019;321(10):983-97.
Rieux C, Brittenham G, Bachir D, De Meyer E, Boudjedir K. French hemovigilance network. Delayed hemolytic transfusion reaction in the French hemovigilance system. Transfus Clin Biol. 2019;26(2):109-11.
Pahuja S, Puri V, Mahajan G, Gupta P, Jain M. Reporting adverse transfusion reactions: A retrospective study from tertiary care hospital from New Delhi, India. Asian J Transfus Sci. 2017;11(1):6-12.
Hindawi SI, Badawi MA, Raj ET, Gholam KA, Al-Weail SO, Azher F. The use of transfusion quality indicators as a tool for hemovigilance system implementation at a tertiary care center in Saudi Arabia. Saudi Med J. 2016;37(5):538-43.
Moncharmont P, Barday G, Odent-Malaure H, Benamara H. Adverse transfusion reactions in recipients transfused in out-of-hospital. Transfus Clin Biol. 2018;25(2):105-8.
Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, et al. Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment. J Patient Rep Outcomes. 2017;2(1):13.
Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168(2):291-300.
Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-37.
Bajpai M, Gupta S, Jain P. Alloimmunization in multitransfused liver disease patients: Impact of underlying disease. Asian J Transfus Sci. 2016;10(2):136-9.
Fasano RM, Chou ST. Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications. Transfus Med Rev. 2016;30(4):197-201. Review.
Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion. 2014; 54(4):972-81.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Vanessa Marques Vilar, Natany da Costa Ferreira, Gislaine Rodrigues Nakasato, Fernando Luiz Lupinacci, Juliana de Lima Lopes, Camila Takao Lopes
This work is licensed under a Creative Commons Attribution 4.0 International License.
